GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Korro Bio Inc.
Shares of Korro Bio, a company developing RNA editing technology, are a venture bet on a new approach to medicine. Their price reflects not current revenues, but investors' faith in the platform's potential for developing drugs for rare diseases.
Share prices of companies in the market segment - Dna
Korro Bio (KRRO) is a biotech company developing a new RNA editing platform that enables targeted changes to genetic code to treat diseases. We classify it as "DNA technologies." The chart below illustrates the dynamics of this cutting-edge and risky biotech sector.
Broad Market Index - GURU.Markets
Korro Bio is a biotech company developing a new class of RNA-based drugs that edit genetic information to treat diseases. As part of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
KRRO - Daily change in the company's share price Korro Bio Inc.
Shares of Korro Bio, an RNA editing company, are extremely volatile. Change_co measures market reactions to news about its scientific platform. This metric is an essential component in building valuation models for leading biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Korro Bio, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with KRRO's performance, with its RNA editing platform, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Korro is a biopharmaceutical company developing RNA-based drugs. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Korro's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Korro Bio Inc.
Korro Bio, Inc.'s year-over-year performance is a story of the development of an innovative RNA editing platform. Its 12-month market cap depends entirely on progress in preclinical research. Each successful experiment confirming the potential of its technology is a fundamental step toward the creation of a new class of drugs.
Annual dynamics of market capitalization of the market segment - Dna
Korro Bio, Inc. is an early-stage biotech company developing a new class of RNA therapeutics. Its stock price is entirely speculative and based on investor confidence in its breakthrough scientific platform, rather than on current financial performance, as is typical for this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Korro Bio is a clinical-stage biotech company whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its innovative platform trials. The company's chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Korro Bio Inc.
The valuation of Korro, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of its unique RNA editing platform, the success of which in preclinical and clinical trials determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Dna
The RNA-editing market is a new frontier in biotechnology, where companies are evaluated based on the potential of their scientific platform. The dynamics of this sector, as seen in the chart, reflect a high degree of uncertainty and speculative interest. Companies like Korro Bio are working at the forefront of this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Korro Bio is an early-stage biotech company. Its shares are steeped in lab data and investor expectations about science. Their value can fluctuate wildly, ignoring macroeconomic events and overall market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Korro Bio Inc.
Korro Bio, a biotech company developing RNA-editing technology for drug discovery, is at the cutting edge of science. Its weekly stock price is a response to preclinical data and scientific hypotheses, reflecting a high degree of risk and potential reward.
Weekly dynamics of market capitalization of the market segment - Dna
Biotech companies developing RNA editing technology, like Korro Bio, are at the cutting edge of science. The chart below shows the general sentiment in this innovative niche. It allows one to assess how promising the market perceives Korro Bio's platform compared to other gene editing companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Korro Bio is a biotech company developing a new method for RNA editing. It's a cutting-edge scientific platform with enormous potential and risks. The chart shows that its stock price is driven by investor faith in the technology, not by macroeconomic data.
Market capitalization of the company, segment and market as a whole
KRRO - Market capitalization of the company Korro Bio Inc.
Korro Bio's market capitalization reflects investors' bets on its innovative RNA-editing platform. The chart reflects the market's belief that its technology, which enables precise edits to RNA, will open up new avenues for treating genetic diseases. Its value is an estimate of the potential of this cutting-edge scientific concept.
KRRO - Share of the company's market capitalization Korro Bio Inc. within the market segment - Dna
Korro Bio is a biotech company developing a novel RNA editing platform that enables the correction of genetic mutations without altering DNA. In the cutting-edge DNA/RNA medicine segment, its market capitalization reflects the revolutionary potential of this approach. The company's size reflects its bet that its technology will prove safe and effective.
Market capitalization of the market segment - Dna
Here's a chart reflecting the combined weight of the entire biotech sector specializing in gene therapy. For Korro Bio, with its innovative RNA editing technology, this line is a map of the future of medicine. The rising chart represents an influx of capital into technologies that promise to treat diseases at a new, even more sophisticated level than DNA editing.
Market capitalization of all companies included in a broad market index - GURU.Markets
Korro Bio is a biotech company developing a new approach to RNA editing for drug discovery. Its market capitalization reflects its cutting-edge scientific platform. While it represents a tiny fraction of the overall market, it represents enormous potential for a new treatment approach.
Book value capitalization of the company, segment and market as a whole
KRRO - Book value capitalization of the company Korro Bio Inc.
Korro Bio is a biotechnology company developing a new class of RNA therapeutics. Its book value is the sum of its financial resources and scientific platform. It consists of cash for R&D and the value of its unique RNA editing technology. How has this capital changed? The chart below shows.
KRRO - Share of the company's book capitalization Korro Bio Inc. within the market segment - Dna
Korro Bio, Inc. is developing a new class of RNA drugs. Its innovative platform requires a modern infrastructure: laboratories equipped for RNA editing and preclinical studies. The chart shows the company's share of the physical R&D infrastructure for this cutting-edge biotechnology field.
Market segment balance sheet capitalization - Dna
Korro Bio, a biopharmaceutical company developing RNA-editing technologies, has a lightweight R&D business. Its strength lies in its scientific platform. The BCap_Seg chart for the biotech sector, which is full of R&D companies, confirms that at this stage, the most important capital is intellectual, not material.
Book value of all companies included in the broad market index - GURU.Markets
Korro Bio's balance sheet isn't its factories, but its patented scientific platform, OPERA, for RNA editing, which allows genetic errors to be corrected without altering DNA. The company's assets are its intellectual capital. The chart below shows how this cutting-edge scientific asset compares to the world of biotechnology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Korro Bio Inc.
Korro Bio's balance sheet is its R&D capital. Its entire market value is a premium on its RNA editing platform. Its price is a bet that its scientific approach will prove a breakthrough in the treatment of genetic diseases.
Market to book capitalization ratio in a market segment - Dna
Korro Bio is a biotech company developing a new RNA editing method. Its high rank on this chart reflects its breakthrough scientific platform, which could open new horizons in the treatment of genetic diseases if proven safe and effective.
Market to book capitalization ratio for the market as a whole
Korro Bio is a biotech company developing a new class of RNA therapeutics. Its market value is based on the potential of its unique scientific platform. Like many early-stage companies, its valuation reflects investors' bets on a future scientific breakthrough, not on its current assets.
Debts of the company, segment and market as a whole
KRRO - Company debts Korro Bio Inc.
Korro Bio, a biotech company developing a novel RNA-editing technology, is in the very early stages. All of the capital raised is being directed toward preclinical studies. This chart reflects the financial strategy of a scientific startup, where all resources are invested in validating a fundamental concept that could transform medicine.
Market segment debts - Dna
Korro Bio is a preclinical biotech company developing a novel RNA editing technology. At this very early stage of development, funding is entirely dependent on venture capital and equity capital, as debt is unavailable. This chart illustrates a purely equity-based financial model.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Korro Bio Inc.
Korro Bio is a biotech company working on RNA editing. This is a cutting-edge scientific field that requires massive investment. This chart shows the company's reliance on external funding. It reflects the company's extremely high financial risk and the bet that its unique technology will lead to the development of a new class of drugs.
Market segment debt to market segment book capitalization - Dna
Korro Bio is developing a new class of drugs (RNA editing) that enables precise changes to genetic code. This is cutting-edge, but very early technology. The chart shows how aggressively the biotech sector uses debt to finance revolutionary ideas, providing context for assessing Korro's risks and potential.
Debt to book value of all companies in the market
Korro Bio, Inc., a company working on RNA editing, is at the forefront of biotechnology, requiring massive investments in research long before revenue is realized. This chart, showing the market's overall debt load, provides context for assessing its risks. It helps understand how the company finances its expensive research and how typical this is for innovative biotech companies.
P/E of the company, segment and market as a whole
P/E - Korro Bio Inc.
Korro Bio is a biotech company developing a new class of RNA-based drugs that can edit individual nucleotides in RNA to treat diseases. This chart shows how the market values its cutting-edge scientific platform. This valuation is based on the potential of this technology to revolutionize genetic medicine.
P/E of the market segment - Dna
Korro Bio is developing RNA-editing technology. This chart shows the average valuation for the biotech sector. It emphasizes that Korro is valued not by profit, but by the revolutionary potential of its scientific platform, which the market can value at a significant premium to the average.
P/E of the market as a whole
Korro Bio, Inc. is a biotech company developing a novel RNA-editing platform that enables targeted changes to genetic code to treat diseases. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether KRRO's high valuation is based on faith in its breakthrough scientific platform or whether it is moving in sync with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Korro Bio Inc.
Korro Bio is developing a new class of RNA drugs that can "edit" genetic information directly in cells. Future profits depend on the success of this cutting-edge technology. This chart shows the market's high, yet speculative, expectations for the company's potential to revolutionize the treatment of genetic diseases.
%20P%2FE%20Korro%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Korro-Bio-Inc.&v=1772573427409 "Chart of the company's future (projected) P/E Korro Bio Inc.")
Future (projected) P/E of the market segment - Dna
Korro Bio is developing a new class of genetic drugs that utilize the body's own system to introduce precise changes to RNA, enabling the treatment of diseases at the genetic level. The data presented here reflects the analysts' collective belief in the success of this cutting-edge and complex scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772573427426 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Korro Bio is developing a new class of RNA drugs that can edit genetic information directly in the body. This is cutting-edge science. This general sentiment chart shows how willing investors are to invest in fundamental biotech platforms with revolutionary potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772573427478 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Korro Bio Inc.
Korro Bio is developing a new RNA editing technology that enables precise changes to the genetic code without altering DNA. This graph shows the financial costs of creating this breakthrough platform. It reflects the investment in science that could lead to a new class of drugs for the treatment of genetic diseases.
Profit of companies in the market segment - Dna
Korro Bio is a biotechnology company developing a novel RNA editing platform that enables genetic mutations to be corrected without altering DNA. While still in its early stages, it represents the cutting edge of science. Its future profitability depends on the success of this breakthrough and complex technology.
Overall market profit
Korro Bio is a biotech company developing a novel RNA-editing platform for treating rare diseases. Its valuation depends on the success of this cutting-edge science. While there's no direct correlation with the economy, the overall state of the markets, reflected in this chart, determines the availability of venture capital, which is the sole lifeline for such companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Korro Bio Inc.
Korro Bio is a biotech company developing a novel RNA editing platform for the creation of new drugs. This chart shows analysts' speculative expectations. Future profits depend entirely on the success of their innovative technology in preclinical and clinical trials.
%20profit%20of%20the%20company%20Korro%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Korro-Bio-Inc.&v=1772573427835 "Graph of future (projected) profit of the company Korro Bio Inc.")
Future (predicted) profit of companies in the market segment - Dna
Korro Bio is a biotech company developing a new RNA-editing platform that allows genetic mutations to be corrected without altering DNA. The profitability forecasts for this sector, shown in the graph, demonstrate the enormous interest in genetic medicine. This chart helps assess how revolutionary Korro's technology could be.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772573427870 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Korro Bio is a biotechnology company developing a novel RNA editing platform. This is a cutting-edge scientific field that requires significant, long-term investment. Investor appetite for funding such fundamental research is highly dependent on overall market conditions, which are improving amid positive economic forecasts.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772573427910 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Korro Bio Inc.
Korro Bio is a biotech company developing a new class of RNA-editing drugs that can correct genetic mutations. It has no commercial revenue. This chart shows how investors value its breakthrough scientific platform, betting that it will lead to fundamentally new treatments.
P/S market segment - Dna
Korro Bio is a biotech company developing a new RNA-editing platform that enables targeted changes in genetic code to treat diseases. This chart shows the average revenue estimate for the biotech sector. It helps understand the market premium for this breakthrough and potentially revolutionary approach to gene therapy.
P/S of the market as a whole
Korro Bio is a biotech company developing a new RNA editing platform. This approach enables precise modifications to RNA to treat genetic diseases. This chart correlates the market's valuation of companies with their actual revenues, which is important for contextualizing the analysis of companies with breakthrough but unproven technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Korro Bio Inc.
Korro Bio is a biotech company developing an RNA-editing platform for the creation of a new class of drugs. This chart reflects investors' high valuation of its potential future revenue. This valuation is a bet on the breakthrough nature of its technology and its application in the treatment of genetic diseases.
%20P%2FS%20Korro%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Korro-Bio-Inc.&v=1772573428223 "The graph of the company's future (projected) P/S Korro Bio Inc.")
Future (projected) P/S of the market segment - Dna
Korro Bio is a biotech company developing a new class of RNA-editing drugs for the treatment of diseases. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. This valuation reflects investor confidence in its innovative platform and ability to develop new therapeutics.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772573428261 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Korro Bio is a preclinical biotechnology company developing a novel RNA-editing technology for the treatment of rare diseases. Its valuation is based entirely on the potential of its scientific platform. This overall market expectation chart is irrelevant for Korro Bio, as its future is determined by success in the laboratory and subsequent clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772573428373 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Korro Bio Inc.
This chart illustrates the revenue of Korro Bio, a biotech company developing a novel RNA-editing technology for the creation of innovative drugs. Being in the preclinical stage, the company has no sales revenue, as the chart confirms. The company's entire value lies in the potential of its scientific platform and future clinical developments.
Sales of companies in the market segment - Dna
Korro Bio is a biotechnology company developing a novel RNA editing platform that enables precise changes to genetic code without DNA modification. This graph shows revenue in the DNA therapeutics sector. It reflects the cutting edge of genetic medicine, where innovative approaches like Korro's platform can offer safer treatments.
Overall market sales
Korro Bio is a biotech company developing a new class of RNA-editing drugs. Its valuation depends on the success of its innovative scientific platform. The overall economic situation shown in this chart does not affect scientific research, but it does provide the backdrop for raising venture capital necessary for costly clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Korro Bio Inc.
Korro Bio is a preclinical biotechnology company developing a new class of genetically modified drugs using RNA editing technology. This revenue projection is purely speculative. It reflects analysts' confidence in the scientific potential of this advanced platform and its ability to lead to commercial products in the distant future.
%20sales%20of%20the%20company%20Korro%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Korro-Bio-Inc.&v=1772573428471 "Schedule of future (projected) sales of the company Korro Bio Inc.")
Future (projected) sales of companies in the market segment - Dna
Korro Bio is a biotechnology company developing a new RNA editing platform. This technology enables precise changes to genetic information without altering DNA. This graph shows projected revenues for the entire DNA therapeutics sector, reflecting interest in new, potentially safer gene editing methods.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772573428505 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Korro Bio is a biotechnology company developing a new class of RNA-editing drugs. Its future depends entirely on scientific discoveries and success in preclinical and clinical trials. A positive financial market environment is essential for attracting the significant capital needed to develop such a breakthrough technology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772573428519 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Korro Bio Inc.
Korro Bio is a biotech company developing a new class of RNA-editing drugs. It is in preclinical research. This chart does not reflect revenue, but rather shows the investment in its innovative scientific platform. It provides a financial picture of the development of a technology that could transform medicine in the future.
Market segment marginality - Dna
Korro Bio is a biotech company developing a new class of RNA-based drugs that utilize the body's natural processes to precisely edit genetic information. This chart reflects its financial performance. For a preclinical company, the comparison with the industry demonstrates how effectively it manages its initial R&D costs.
Market marginality as a whole
Korro Bio is a biotech company developing an innovative RNA editing platform. Its success depends solely on scientific breakthroughs and the results of preclinical and clinical trials, not on the economic situation, as reflected in this chart. The potential of this technology is enormous.
Employees in the company, segment and market as a whole
Number of employees in the company Korro Bio Inc.
Korro Bio is a biotech company developing a novel RNA-editing technology to create treatments for rare diseases. This graph shows a small team of scientists. A small staff is typical for a preclinical stage company. Growth will indicate successful advancement of its innovative platform.
Share of the company's employees Korro Bio Inc. within the market segment - Dna
Korro Bio is a biotech company developing a novel RNA editing technology. While in the research stage, it has a small but elite team of scientists. This graph illustrates its focus: its minimal staff means the company's entire value is concentrated in its innovative scientific platform and intellectual property.
Number of employees in the market segment - Dna
Korro Bio is a biotech company developing an innovative RNA-editing platform that allows genetic mutations to be corrected without altering DNA. This graph shows the earliest, most research-intensive stage of development. A small team of scientists is working to validate this cutting-edge concept. Success could open a new avenue for medicine.
Number of employees in the market as a whole
Korro Bio is a biotechnology company developing a new class of RNA drugs capable of editing individual nucleotides. Its staff includes a team of scientists working at the forefront of genetics. This employment graph demonstrates that in the world of breakthrough biotech, job creation is driven not by economics, but by the potential for scientific discoveries to transform medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Korro Bio Inc. (KRRO)
Korro Bio is a biotech company developing a new RNA editing platform that enables precise modifications to nucleic acids to treat genetic diseases. This chart demonstrates the company's enormous value per scientist. The market capitalization reflects the company's high valuation of its unique technological platform, not its current operations.
%20of%20the%20company%20Korro%20Bio%20Inc.%20(KRRO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Korro-Bio-Inc.-KRRO&v=1772573429128 "Chart of market capitalization per employee (in thousands of dollars) of the company Korro Bio Inc. (KRRO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Korro Bio is a biotech company developing a new RNA editing platform. In this cutting-edge field of genetics, the company's value is a bet on a future breakthrough. This chart shows the enormous premium investors are placing on their unique technology and the team of scientists capable of creating a new class of drugs.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772573429188 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Korro Bio is developing a new class of RNA drugs that can edit genetic information. This figure reflects a business at the cutting edge of science. Its market capitalization is entirely based on the promise of this unique platform. Even a small team of scientists could be worth hundreds of millions if their technology proves effective.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772573429296 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Korro Bio Inc. (KRRO)
Korro Bio is a preclinical biotech company developing an RNA editing platform. This is cutting-edge science. They are not profitable. This graph shows the loss per employee. This is the cost of maintaining an R&D team working on a fundamentally new class of drugs.
%20Chart%20Korro%20Bio%20Inc.%20(KRRO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Korro-Bio-Inc.-KRRO&v=1772573429349 "Company Profit Per Employee (in thousands of dollars) Chart Korro Bio Inc. (KRRO)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Korro Bio is a preclinical biotech company focused on RNA editing. The company is unprofitable. It's at the cutting edge of early-stage research. This metric reflects the R&D capital burn per employee—essentially the cost of working at the cutting edge of genetic medicine.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772573429407 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Korro Bio is a biotech company working on RNA editing technology to create new drugs. They are in the early, preclinical stage. This chart doesn't show profit; it shows the amount of investment burned per scientist to fund and develop this cutting-edge, yet highly risky, scientific platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772573429426 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Korro Bio Inc. (KRRO)
Korro Bio is a biotech company developing a new RNA editing platform. This schedule is typical for a company in the preclinical stage. The lack of revenue per employee means all resources are focused on developing their breakthrough scientific technology, which has not yet reached human trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Korro-Bio-Inc.-KRRO&v=1772573429485 "Sales chart per company employee Korro Bio Inc. (KRRO)")
Sales per employee in the market segment - Dna
Korro Bio (KRRO) is a biotech company developing a new RNA editing platform. This enables the correction of genetic mutations at the RNA level. This graph shows the revenue (if any) generated by each employee (scientist). It's an indicator of the productivity of their cutting-edge R&D platform at an early stage.
Sales per employee for the market as a whole
Korro Bio (KRRO) is a biopharmaceutical company developing a novel RNA editing platform for the creation of innovative drugs. This is an early-stage (preclinical) R&D company. The company has no revenue, and its revenue is close to zero.
Short shares by company, segment and market as a whole
Shares shorted by company Korro Bio Inc. (KRRO)
Korro Bio is a biotech company working in the cutting-edge field of RNA editing. This chart shows bearish bets. Bears are betting that the technology is too crude, hasn't proven its safety and efficacy, and that the company will burn through all of its investors' capital long before achieving any commercial success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Korro-Bio-Inc.-KRRO&v=1772573429623 "Short Shares Chart for the Company Korro Bio Inc. (KRRO)")
Shares shorted by market segment - Dna
Korro Bio is a biotech company developing an RNA-editing platform for the creation of new drugs. This chart shows bearish sentiment. The "shorts" here are betting that their cutting-edge, yet highly complex, scientific platform will fail or fail to reach clinical trials.
Shares shorted by the overall market
Korro Bio is a biotech company working on RNA editing to create new drugs. This is one of the most advanced fields in science. This chart shows the overall level of market fear. When panic mounts, investors are quick to sell the riskiest and most difficult-to-understand scientific concepts, preferring cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Korro Bio Inc. (KRRO)
Korro Bio (KRRO) is a biotech company focused on RNA editing. They are developing drugs that can correct errors in RNA to treat rare diseases. This is a speculative R&D bet. This chart measures hype. It shows "overheated" (above 70) during positive R&D data or "oversold" (below 30) during periods of anticipation and high uncertainty.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Korro-Bio-Inc.-KRRO&v=1772573429850 "RSI 14 indicator chart for the company's stock Korro Bio Inc. (KRRO)")
RSI 14 Market Segment - Dna
Korro Bio (KRRO) is a biotech company working on RNA editing—fine-tuning genetics without cutting DNA. The RSI_14_Seg for "Dna" (biotech) shows the overall sentiment in the sector. The chart helps us understand: is KRRO's volatility a reflection of their platform, or is the entire sector overheated?
RSI 14 for the overall market
Korro Bio (KRRO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KRRO (Korro Bio Inc.)
Korro Bio is a biotech company developing a new RNA editing technology. Their platform enables precise modifications to RNA to treat rare diseases. This chart shows the average 12-month forecast of analysts, representing their collective speculative bet on the success of this early-stage scientific platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KRRO-Korro-Bio-Inc.&v=1772573430030 "A chart showing analyst consensus forecasts for the expected stock price. KRRO (Korro Bio Inc.)")
The difference between the consensus estimate and the actual stock price KRRO (Korro Bio Inc.)
Korro Bio is a biotech company developing a new RNA editing platform (EDIT). Their goal is to precisely edit genetic instructions in cells. This chart shows how much upside or downside analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in this cutting-edge science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KRRO-Korro-Bio-Inc.&v=1772573430056 "A chart showing the difference between the consensus forecast and the actual stock price. KRRO (Korro Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Korro Bio is a biotech company developing a new RNA editing technology that enables precise changes to genetic code to treat diseases. This chart shows general expectations for the DNA technology sector, reflecting experts' confidence in this cutting-edge, yet risky, R&D platform.
Analysts' consensus forecast for the overall market share price
Korro Bio is a biotech company developing an RNA editing platform that enables precise modifications to RNA to treat diseases. This chart shows the overall risk appetite. For Korro, which operates in one of the most advanced and risky areas of medicine, overall market optimism is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Korro Bio Inc.
Korro Bio is a biotech company working in the cutting-edge field of RNA editing. Their platform (OPERA) enables precise edits to RNA to correct diseases at the protein level, without affecting DNA. This graph is a pure assessment of their R&D platform. Its dynamics depend entirely on their progress in preclinical research and their confidence in their new scientific modality.
AKIMA Market Segment Index - Dna
Korro Bio (KRRO) is a clinical-stage biotech and a pioneer in RNA editing. The company is developing a breakthrough R&D platform (EDIT) that enables precise edits to RNA to treat rare diseases. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this futuristic (R&D) bet (KRRO) differentiate it from the average pharma company?
The AKIM Index for the overall market
Korro Bio is a biotech company developing RNA-editing technologies to treat genetic diseases (AAT deficiency). This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this cutting-edge scientific platform at an early stage.
